Screening and Evaluation of Patients with Signs and Symptoms of Alzheimer's Disease
The purpose of this study is to determine the eligibility of individuals for Alzheimer's disease clinical trials.
|Minimum Age||Maximum Age||Gender||Healthy Volunteers|
|45 Years||N/A||Both||Accepts Healthy Volunteers|
++Age 45 or older++History of progressive memory impairment++Caregiver who is willing to accompany the subject to the National Institutes of Health Clinical Center
++Diagnosis of a non-Alzheimer's dementia, including frontotemporal dementia, normal pressure hydrocephalus, Lewy body dementia, Parkinson's disease dementia, Huntington's disease, or vascular dementia ++Pregnant women; women of childbearing potential will be screened by history for the possibility of pregnancy and undergo a urine pregnancy test ++Any medical contraindication to the procedures performed in the study or any current severe medical or psychiatric illness other than Alzheimer's++Behavioral symptoms that preclude the gathering of data for the study or advanced disease such that volunteers cannot provide assent
Individuals who demonstrate symptoms of Alzheimer's disease, such as progressive memory loss, may be eligible to participate in National Institutes of Health research studies. However, other physical and psychological conditions may produce symptoms similar to those of Alzheimer's. To determine whether a patient meets the eligibility criteria to participate in a research study, researchers must perform a series of diagnostic tests and procedures. These evaluations are designed to evaluate a participant's general medical condition (using, for example, blood tests and neurological exams) and to confirm a diagnosis or rule out an individual for consideration.
Required tests and procedures for various research studies may include the following: medical history and physical examination, including a psychiatric evaluation; neuropsychological tests to test memory, mood, concentration, and thought processes; blood and urine tests; and imaging studies (X-rays, magnetic resonance imaging, computerized tomography, positron emission tomography. After all eligibility assessments are complete, participants may be offered participation in one or more research protocols.
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Bethesda||Maryland||20892||
|William C. Kreisl, MD||Principal Investigator||National Institute of Mental Health (NIMH)|
|Meghan S. McGwierfirstname.lastname@example.org|
- Gorshow S. Alzheimer`s disease and managed care: a convincing case for action. Manag Care Interface. 2007 Mar;20(3):26-7. Erratum in: Manag Care Interface. 2007 Jun;20(6):32.
- Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord. 2006;21(3):175-81. Epub 2006 Jan 9.
- Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O`brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer`s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007 Aug;6(8):734-46. Review.